Analysis of changes in the levels of soluble molecules CD50, CD54 and CD95 in the blood serum of patients with uterine fibroids depending on the characteristics of the disease (pilot study)

Cover Page

Cite item

Full Text

Abstract

Background. Currently, the search for circulating immunological and inflammatory markers that play a significant role in the pathogenesis of uterine fibroids (UF) is relevant.

Aim. Changes in the serum levels of soluble molecules CD50 (sCD50), CD54 (sCD54) and CD95 (sCD95) in patients with UF depending on the characteristics of the disease.

Materials and methods. The study involved 78 patients with UF aged 31–59 years and 45 clinically healthy women of comparable age. The patients were divided into the following groups depending on the localization of the myomatous node: interstitial-subserous localization (n = 17), subserous localization (n = 16), submucosal localization (n = 15), interstitial-submucosal localization (n = 15), interstitial localization (n = 15). In 34.6 % patients, the number of myoma nodes was 4–6, in 46.2 % women there were 2–3 nodes, in 19.2 % – 1 node.

Determination of the serum concentration of sCD50, sCD54 and sCD95 molecules was performed using a two-site enzyme immunoassay and expressed in conventional units (U / ml).

Results. The average serum concentration of sCD95, sCD54 and sCD50 in all patients with UF was significantly higher than in the control group (p <0.05). The maximum level of the tested molecules was found in UF patients with submucosal localization and the presence of one myomatous node.

Conclusions. The detected increase in sCD50, sCD54 and sCD95 levels in UF patients indicates the participation of these proteins in the immunopathogenesis of this pathology. The imbalance in studied proteins levels is most pronounced in submucosal localization of fibroids, which may indicate an unfavorable course of the disease and serve as an additional criterion for selecting patients in the preoperative period.

About the authors

A. V. Alyasova

Privolzhsky Research Medical University, Ministry of Health of Russia

ORCID iD: 0000-0003-2621-0359

Anna V. Alyasova

10 / 1 Minina and Pozharskogo Square, Nizhny Novgorod 603950

Russian Federation

M. E. Mamaeva

Privolzhsky District Medical Center of the Federal Medical and Biological Agency

ORCID iD: 0000-0001-5961-7986

Marina E. Mamaeva

2 Nizhnevolzhskaya nab., Nizhny Novgorod 603005

Russian Federation

N. I. Kubysheva

Kazan (Volga region) Federal University

Author for correspondence.
Email: aibolit70@mail.ru
ORCID iD: 0000-0002-5582-5814

Nailya I. Kubysheva

18 Kremlyovskaya St., Kazan 420000

Russian Federation

V. V. Novikov

I.N. Blokhina Nizhny Novgorod Research Institute of Epidemiology and Microbiology, Federal Service for Supervision of Consumer Rights Protection and Human Welfare; National Research Lobachevsky State University of Nizhny Novgorod

ORCID iD: 0000-0002-2449-7213

Viktor V. Novikov

71 Malaya Yamskaya St., Nizhny Novgorod 603950

23 Prospekt Gagarina, Nizhny Novgorod 603022 

Russian Federation

References

  1. Mathew R.P., Francis S., Jayaram V., Anvarsadath S. Uterine leiomyomas revisited with review of literature. Abdom Radiol (NY) 2021;46(10):4908–26. doi: 10.1007/s00261-021-03126-4
  2. Dvorská D., Škovierová H., Braný D. et al. Liquid biopsy as a tool for differentiation of leiomyomas and sarcomas of corpus uteri. Int J Mol Sci 2019;20(15):3825. doi: 10.3390/ijms20153825
  3. AlAshqar A., Reschke L., Kirschen G.W., Borahay M.A. Role of inflammation in benign gynecologic disorders: from pathogenesis to novel therapies. Biol Reprod 2021;105(1):7–31. DOI: https://doi.org/10.1093/biolre/ioab054
  4. Sahar T., Nigam A., Anjum S. et al. Interactome analysis of the differentially expressed proteins in uterine leiomyoma. Anticancer Agents Med Chem 2019;19(10):1293–312. doi: 10.2174/1871520619666190206143523
  5. Governini L., Marrocco C., Semplici B. et al. Extracellular matrix remodeling and inflammatory pathway in human endometrium: insights from uterine leiomyomas. Fertil Steril 2021; 116 (5): 1404–14. doi: 10.1016/j.fertnstert.2021.06.023
  6. Protic O., Toti P., Islam M.S. et al. Possible involvement of inflammatory/reparative processes in the development of uterine fibroids. Cell Tissue Res 2016;364(2):415–27. doi: 10.1007/s00441-015-2324-3
  7. Zannotti A., Greco S., Pellegrino P. et al. Macrophages and immune responses in uterine fibroids. Cells 2021;10(5):982. doi: 10.3390/cells10050982
  8. Szydłowska I., Grabowska M., Nawrocka-Rutkowska J. et al. Markers of inflammation and vascular parameters in selective progesterone receptor modulator (ulipristal acetate)-treated uterine fibroids. J Clin Med 2021;10(16):3721. doi: 10.3390/jcm10163721
  9. Malyshkina A.I., Sotnikova N.J., Posiseeva L.V., Antzyferova J.S. Immune parameters of the peritoneal fluid in uterine myoma. Prognostic relevance. Medicinskaja immunologija = Medical Immunology (Russia) 2005;7(4):437–40. (In Russ.). doi: 10.15789/1563-0625-2005-4-437-440
  10. Konenkov V.I., Koroleva E.G., Orlov N.B. et al. Blood serum levels of proinflammatory cytokines (IL-1β, IL-6, TNFα, IL-8, IL-12p70, and IFNγ) in patients with uterine myoma. Bull Exp Biol Med 2018;165(5):698–701. doi: 10.1007/s10517-018-4245-0
  11. Sikorski R., Kapeć E., Zaleska W. Serum levels of proinflammatory cytokines in women with uterine myomas. Ginekol Pol 2001;72(12A):1485–8. PMID: 11883301
  12. Novikov V.V., Karaulov A.V. Storm of soluble differentiation molecules in COVID-19. Immunologiya 2022;43(4):458–67. doi: 10.33029/0206-4952-2022-43-4-458-467
  13. Bleijs D.A., Geijtenbeek T.B., Figdor C.G., van Kooyk Y. DC-SIGN and LFA-1: a battle for ligand. Trends Immunol 2001;22(8):457–63. doi: 10.1016/S1471-4906(01)01974-3
  14. Wu M., Tong X., Wang D. et al. Soluble intercellular cell adhesion molecule-1 in lung cancer: A meta-analysis. Pathol Res Pract 2020;216(10):153029. doi: 10.1016/j.prp.2020.153029
  15. Kovács P., Joó J.G., Tamás V. et al. The role of apoptosis in the complex pathogenesis of the most common obstetrics and gynaecology diseases. Physiol International 2020;107(1):106–19. doi: 10.1556/2060.2020.00014
  16. Guégan J.P., Ginestier C., Charafe-Jauffret E. et al. CD95/Fas and metastatic disease: What does not kill you makes you stronger. Semin Cancer Biol 2020;60:121–31. doi: 10.1016/j.semcancer.2019.06.004
  17. Basta P., Mach P., Pitynski K. et al. Differences in the blood serum levels of soluble HLA-G concentrations between the menstrual cycle phases and menopause in patients with ovarian endometriosis and uterine leiomyoma. Neuro Endocrinol Lett 2009;30:91–8. PMID: 19300397
  18. Mamaeva М.Е., Novikov D.V., Alyasova А.V. et al. The content of oligomeric and total fractions of soluble CD38 molecules in blood serum of patients with hysteromyoma. Sovremennye tehnologii v medicine = Modern Technologies in Medicine 2014;6(4):140. (In Russ.).
  19. Mamaeva М.Е., Shumilova S.V., Kazatskaya Zh.А. et al. The content of soluble HLA Class I and HLA-DR molecules in serum in patients with uterine cervix and body pathology. Sovremennye tehnologii v medicine = Modern Technologies in Medicine 2014;6(2):85. (In Russ.).

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-53039 от  04.03.2013.